27 Sep Psychedelic Medicine Market Could Triple by 2035. Are We Ready to Understand It?
Psychedelics are showing up in clinical trials, FDA discussions, and now market forecasts. That is a lot of attention for a subject that, until recently, most people heard about through rumors and documentaries.
A new IndexBox forecast says its global psychedelic drugs market index could reach about 325 by 2035, with 2025 set at 100. That suggests a market more than three times the baseline size. It is a projection, not a guarantee, and it does not mean every psychedelic therapy has been approved or that every product marketed with mushroom imagery has medical benefits.
At Chillum, we hear the questions people ask when a headline like that appears: What is actually being studied? What is legal? What has the FDA approved? And how do you tell real research from a sales pitch?
Our friends at Learn Euphoria took a closer look at the forecast and the hard questions behind it, including the cost of supervised care, regulatory hurdles, and why education needs to keep pace with the industry.
Read the full article on Learn Euphoria: Psychedelic Drugs Market Forecast to 2035.
The market may grow. Understanding what the science does—and does not—say is a better place to start.
This article is for education, not medical advice. No retail product discussed here is presented as a treatment for a medical condition.
No Comments